Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin
نویسندگان
چکیده
Background Approximately 30% of HIV-infected patients are coinfected with hepatitis C (HCV). The current treatment standard of care for HCV, pegylated interferon and ribavirin (RBV), has demonstrated a sustained virologic response (SVR) in less than 50% of HCV/HIV coinfected patients, and only 17-35% in HCV genotype 1 patients. It has been previously shown that using a weight-based RBV dose results in favorable SVR rates. Prior studies suggest that HCV/HIV co-infected patients receiving a HAART regimen that included tenofovir (TDF) had higher SVR rates than those who received abacavir (ABC) in their nucleos(t)ide analogue (N(t)RTI) backbone.
منابع مشابه
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
OBJECTIVES To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of abacavir plus lamivudine with that observed in subjects who receive tenofovir plus lamivudine or emtricitabine. METHODS A total of 256 subjects, enrolled in a cohort of...
متن کاملEffect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord
BACKGROUND Contradicting results on the effect of abacavir (ABC) on hepatitis C virus (HCV) treatment responses in HIV/HCV co-infected patients have been reported. We evaluated the influence of ABC on the response to pegylated interferon (pegIFN) and ribavirin (RBV)-containing HCV treatment in HIV/HCV co-infected patients in a large European cohort collaboration, including data from different E...
متن کاملAbacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.
BACKGROUND HCV is a major cause of morbidity and mortality in HIV-coinfected patients. Several observational studies have suggested that HCV response to pegylated interferon and ribavirin is lower in HIV-coinfected patients treated with abacavir. It has been postulated that abacavir could compete with ribavirin to be phosphorylated, leading to a reduction in the active form of the drug (triphos...
متن کاملبررسی ژنوتیپهای ویروس هپاتیت C در مراجعین به کلینیک مرجع استان یزد
Introduction: Determining virus genotype is a major factor for initiation of treatment because various kinds of genotypes need different antiviral drugs. Distribution of hepatitis C genotype in the word is variable in each country or even in each province. So we need to determine distribution pattern of hepatitis C genotype in our region. This study was performed in referral clinic of Yazd prov...
متن کاملRibavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?
OBJECTIVE(S) To examine the impact of ribavirin and abacavir coadministration on hepatitis C virus (HCV) virological response and trough ribavirin plasma concentration (Cmin) in HIV-HCV coinfected patients. DESIGN Pharmacokinetic substudy on patients from the ANRS CO-13 HEPAVIH cohort. METHODS Patients receiving ribavirin-pegylated interferon for whom a ribavirin steady state Cmin was prosp...
متن کامل